Raymond James Trust N.A. Has $200,000 Position in Organon & Co. (NYSE:OGN)

Raymond James Trust N.A. lifted its holdings in Organon & Co. (NYSE:OGN) by 7.6% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 13,868 shares of the company’s stock after acquiring an additional 983 shares during the period. Raymond James Trust N.A.’s holdings in Organon & Co. were worth $200,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. Kahn Brothers Group Inc. lifted its position in Organon & Co. by 0.6% during the fourth quarter. Kahn Brothers Group Inc. now owns 62,634 shares of the company’s stock worth $1,749,000 after purchasing an additional 366 shares during the period. Kentucky Retirement Systems Insurance Trust Fund lifted its position in Organon & Co. by 5.2% during the third quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 9,114 shares of the company’s stock worth $213,000 after purchasing an additional 449 shares during the period. Fairfield Bush & CO. lifted its position in Organon & Co. by 3.0% during the first quarter. Fairfield Bush & CO. now owns 16,302 shares of the company’s stock worth $569,000 after purchasing an additional 481 shares during the period. Cresset Asset Management LLC lifted its position in Organon & Co. by 3.7% during the first quarter. Cresset Asset Management LLC now owns 13,969 shares of the company’s stock worth $488,000 after purchasing an additional 493 shares during the period. Finally, Capital Research Global Investors lifted its position in Organon & Co. by 0.7% during the first quarter. Capital Research Global Investors now owns 71,903 shares of the company’s stock worth $2,512,000 after purchasing an additional 513 shares during the period. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Organon & Co.

In related news, insider Kirke Weaver acquired 2,720 shares of Organon & Co. stock in a transaction dated Thursday, February 22nd. The stock was bought at an average price of $18.36 per share, with a total value of $49,939.20. Following the transaction, the insider now directly owns 15,181 shares in the company, valued at approximately $278,723.16. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 1.17% of the company’s stock.

Organon & Co. Price Performance

Organon & Co. stock opened at $18.45 on Thursday. The business has a 50 day moving average of $17.47 and a 200-day moving average of $15.65. Organon & Co. has a 1 year low of $10.84 and a 1 year high of $24.79. The company has a market capitalization of $4.72 billion, a P/E ratio of 4.61, a P/E/G ratio of 0.84 and a beta of 0.81.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Thursday, February 15th. The company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.14. The company had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.55 billion. Organon & Co. had a negative return on equity of 212.00% and a net margin of 16.33%. Equities analysts anticipate that Organon & Co. will post 4.08 EPS for the current year.

Organon & Co. Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 14th. Shareholders of record on Monday, February 26th were given a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a yield of 6.07%. The ex-dividend date of this dividend was Friday, February 23rd. Organon & Co.’s dividend payout ratio is presently 28.00%.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group increased their target price on shares of Organon & Co. from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Tuesday, February 20th.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.